Maureen Oliveira
Overview
Explore the profile of Maureen Oliveira including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1723
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brenner B, Ibanescu R, Oliveira M, Margaillan G, Lebouche B, Thomas R, et al.
Viruses
. 2024 Aug;
16(8).
PMID: 39205204
Background: HIV drug resistance (HIV-DR) may jeopardize the benefit of antiretroviral therapy (ART) in treatment and prevention. This study utilized viral phylogenetics to resolve the influence of transmission networks on...
2.
Brenner B, Oliveira M, Ibanescu R, Routy J, Thomas R
J Antimicrob Chemother
. 2023 Jun;
78(8):1921-1928.
PMID: 37303226
Objectives: The NNRTI doravirine has been recently approved for the first-line treatment of HIV-infected patients, eliciting favourable responses against viruses bearing the K103N, Y181C and G190A mutations. This study used...
3.
Brenner B, Ibanescu R, Osman N, Cuadra-Foy E, Oliveira M, Chaillon A, et al.
Viruses
. 2021 Aug;
13(8).
PMID: 34452506
Phylogenetics has been advanced as a structural framework to infer evolving trends in the regional spread of HIV-1 and guide public health interventions. In Quebec, molecular network analyses tracked HIV...
4.
Brenner B, Oliveira M, Ibanescu R, Routy J, Thomas R
J Antimicrob Chemother
. 2021 Apr;
76(8):2137-2142.
PMID: 33855437
Background: The newer generation NNRTIs, including doravirine and rilpivirine, were designed to show high potency and overcome K103N, Y181C and G190A resistance. Objectives: To assess emergent resistance to doravirine and...
5.
Medina-Moreno S, Zapata J, Kashanchi F, Le N, Hassounah S, Mesplede T, et al.
J Glob Antimicrob Resist
. 2020 Feb;
20:316-317.
PMID: 32061877
No abstract available.
6.
Oliveira M, Ibanescu R, Anstett K, Mesplede T, Routy J, Robbins M, et al.
Retrovirology
. 2018 Aug;
15(1):56.
PMID: 30119633
Background: Integrase strand transfer inhibitors (INSTIs) are recommended for first-line HIV therapy based on their relatively high genetic barrier to resistance. Although raltegravir (RAL) and elvitegravir (EVG) resistance profiles are...
7.
Osman N, Mesplede T, Oliveira M, Hassounah S, Wainberg M, Brenner B
AIDS
. 2018 Jun;
32(13):1773-1780.
PMID: 29894388
Objectives: Dolutegravir (DTG) has achieved better long-term suppression of HIV-1 replication than other integrase strand transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir (EVG). In in-vitro drug washout experiments,...
8.
Oliveira M, Brenner B, Xu H, Ibanescu R, Mesplede T, Wainberg M
J Antimicrob Chemother
. 2017 Sep;
72(11):3008-3011.
PMID: 28961903
Background: 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a potent nucleoside analogue inhibitor of HIV that has an unusually long half-life. Cell culture selections with either EFdA or lamivudine using both subtype B and...
9.
Hassounah S, Alikhani A, Oliveira M, Bharaj S, Ibanescu R, Osman N, et al.
Antimicrob Agents Chemother
. 2017 Sep;
61(12).
PMID: 28923862
Animal models are essential to study novel antiretroviral drugs, resistance-associated mutations (RAMs), and treatment strategies. Bictegravir (BIC) is a novel potent integrase strand transfer inhibitor (INSTI) that has shown promising...
10.
Xu H, Colby-Germinario S, Hassounah S, Fogarty C, Osman N, Palanisamy N, et al.
Sci Rep
. 2017 Jul;
7(1):6345.
PMID: 28740124
We evaluated Sofosbuvir (SOF), the anti-hepatitis C virus prodrug of β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine-5'-monophosphate, for potential inhibitory activity against DENV replication. Both cell-based and biochemical assays, based on use of purified DENV full-length...